Skip to content
Markets News
Stocks1 min read

Moderna Falls Despite Positive Melanoma Trial Results

Makkler Newsroom
October 26, 2026 · Based on reporting by finanzen.net, MarketWatch

The vaccine cut the risk of melanoma recurrence or death, but Moderna shares fell as investors weighed expectations and pipeline risks.

Key takeaways

  • The Phase 3 melanoma trial reported a 42% lower risk of recurrence or death with the vaccine combination.
  • Moderna shares fell after the results, while BioNTech reported both a new study collaboration and a trial setback.

Moderna and Merck said their Phase 3 melanoma trial found that adding Moderna’s personalized cancer vaccine to Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. Moderna shares fell sharply after the results, which may have failed to meet high investor expectations.

The study included 1,137 patients. At two years, 82.2% of patients receiving the combination had not had a recurrence, compared with 70.0% in the Keytruda-only group. At 13:54 UTC Monday, Moderna shares were at $200.85, up 0.37% from the previous close.

BioNTech said its Phase 3 ROSETTA Breast-01 study will switch, subject to regulatory approval, to testing pumitamig with Gilead’s Trodelvy. The company also reported that its BNT113 study in HPV16-positive head and neck cancer missed its primary endpoint; the trial continues to assess overall survival.

Topics
MRNAMRKBNTXGILDMerckGilead Sciences
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.